GlassScriptPhysician profile
Qamar Ul Zaman
NPI 1093893331
$98,292.16
in general payments reported to CMS, 2019-2025
74 companies · $11K in 2025
The $11K reported for 2025 was more than what 89% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $23K · 2020: $8,251 · 2021: $14K · 2022: $23K · 2023: $8,665 · 2024: $9,997 · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $14K · Food and Beverage: $8,605 · Honoraria: $2,860 · Travel and Lodging: $2,571 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,000 · Education: $436.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $13,532.50 |
| Food and Beverage | $8,605.17 |
| Honoraria | $2,860.00 |
| Travel and Lodging | $2,571.20 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,000.00 |
| Education | $435.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $15,139.24 | 2019-2025 | Tagrisso, Imfinzi, Truqap |
| Exelixis INC. | $9,167.54 | 2019-2025 | Cabometyx |
| Sobi, INC | $8,999.34 | 2022-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $6,935.03 | 2019-2025 | |
| Dova Pharmaceuticals | $5,962.95 | 2019-2020 | |
| Pharmacosmos Therapeutics INC. | $5,483.91 | 2020-2023 | Monoferric |
| Incyte Corporation | $5,168.06 | 2019-2025 | Jakafi, Pemazyre, Monjuvi |
| Gilead Sciences, INC. | $4,921.55 | 2019-2025 | Trodelvy |
| Celgene Corporation | $4,537.55 | 2019-2024 | Reblozyl, Pomalyst |
| Avyxa Pharma, LLC | $4,109.40 | 2025 | |
| Amgen INC. | $2,726.40 | 2019-2023 | Lumakras |
| Glaxosmithkline, LLC. | $2,461.60 | 2019-2025 | Zejula, Jemperli, Ojjaara |
| Mirati Therapeutics, INC. | $1,964.11 | 2023-2024 | Krazati |
| Taiho Oncology, INC. | $1,759.48 | 2019-2025 | |
| Daiichi Sankyo INC. | $1,708.02 | 2021-2025 | Enhertu, Datroway |
Show all 74 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $1,450.00 | 2019-2020 | |
| Aveo Pharmaceuticals, INC. | $1,307.94 | 2021-2025 | Fotivda |
| Janssen Biotech, INC. | $1,232.58 | 2019-2025 | Tecvayli, Darzalex, Talvey |
| Merck Sharp & Dohme LLC | $1,081.47 | 2019-2025 | Keytruda, Welireg, Lynparza |
| Pfizer INC. | $1,010.05 | 2019-2025 | |
| Janssen Scientific Affairs, LLC | $1,010.00 | 2022 | |
| Eisai INC. | $916.80 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $792.78 | 2019-2025 | |
| Medtronic USA, INC. | $705.86 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $663.86 | 2019-2025 | Fruzaqla, Alunbrig, Ninlaro |
| Astellas Pharma US INC | $642.24 | 2020-2025 | Padcev, Vyloy |
| Beigene USA, INC. | $633.48 | 2020-2025 | Tevimbra, Brukinsa |
| Emd Serono, INC. | $551.75 | 2020-2025 | Bavencio |
| Beigene, LTD. | $525.00 | 2021 | |
| Seagen INC. | $427.86 | 2019-2024 | Tivdak, Tukysa |
| E.R. Squibb & Sons, L.L.C. | $410.06 | 2019-2025 | Opdivo, Abecma, Reblozyl |
| Abbvie INC. | $301.81 | 2019-2025 | |
| Geron Corporation | $295.97 | 2025 | Rytelo |
| Genentech USA, INC. | $221.47 | 2019-2025 | Venclexta, Itovebi, Tecentriq |
| Genzyme Corporation | $214.37 | 2019-2024 | |
| Pharmacyclics LLC, An Abbvie Company | $206.94 | 2019-2023 | Imbruvica |
| Array Biopharma INC | $204.38 | 2020-2025 | Braftovi, Mektovi, Tukysa |
| Novocure Gmbh | $200.00 | 2022 | |
| Janssen Pharmaceuticals, INC | $167.00 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $133.55 | 2024-2025 | Libtayo |
| Boston Scientific Corporation | $132.73 | 2025 | Watchman Flx |
| Rigel Pharmaceuticals, INC. | $125.08 | 2019-2025 | Gavreto, Tavalisse, Rezlidhia |
| Karyopharm Therapeutics INC. | $123.10 | 2021-2023 | Xpovio |
| Adc Therapeutics America, INC. | $112.43 | 2022-2025 | |
| Puma Biotechnology, INC. | $112.37 | 2020-2025 | |
| Morphosys, US INC. | $106.24 | 2021-2023 | Monjuvi |
| Sumitomo Pharma America, INC. | $94.95 | 2024-2025 | Orgovyx |
| Eusa Pharma (US) LLC | $80.69 | 2020-2022 | |
| Genmab U.S., INC. | $79.06 | 2023-2024 | Epkinly |
| Clovis Oncology, INC. | $77.96 | 2019-2021 | |
| Pharmaessentia USA Corporation | $68.58 | 2024-2025 | Besremi |
| Beone Medicines USA, INC. | $68.22 | 2025 | Tevimbra, Brukinsa |
| Kite Pharma, INC. | $66.75 | 2021-2023 | Yescarta |
| Myriad Genetic Laboratories, INC. | $61.94 | 2023-2024 | Myrisk |
| Foundation Medicine, INC. | $60.92 | 2019-2023 | |
| Pharmaand Gmbh | $60.35 | 2025 | Rubraca |
| Tolmar, INC. | $60.35 | 2025 | Rubraca, Eligard |
| Blueprint Medicines Corporation | $59.43 | 2021-2022 | |
| Servier Pharmaceuticals LLC | $50.12 | 2022-2024 | |
| Caris Mpi, INC. | $49.78 | 2025 | Mi Cancer Seek |
| Lilly USA, LLC | $39.47 | 2021 | |
| Deciphera Pharmaceuticals INC. | $37.45 | 2021-2023 | Qinlock |
| Verastem, INC. | $29.65 | 2019 | |
| Tersera Therapeutics LLC | $28.35 | 2023 | Xermelo |
| Abbott Laboratories | $23.74 | 2025 | Cardiomems |
| Agios Pharmaceuticals, INC. | $20.92 | 2019 | |
| Amag Pharmaceuticals, INC. | $16.59 | 2019 | |
| G1 Therapeutics, INC. | $15.15 | 2022 | |
| Fortovia Therapeutics, INC. | $14.89 | 2019 | |
| Acrotech Biopharma INC. | $13.93 | 2021 | |
| Tactile Systems Technology INC | $13.26 | 2020 | |
| Tesaro, INC. | $13.15 | 2019 | |
| Btg International INC. | $12.05 | 2020 | |
| Coherus Oncology, INC. | $11.11 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Qamar Zaman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.